肝细胞癌患者血清癌基因和抑癌基因蛋白水平变化

doi:10.3969/j.issn.1672-5069.2021.02.024

Abstract

Abstract: Objective The aim of this study was to investigate serum oncogene and tumor suppressor gene level changes in patients with hepatocellular carcinoma (HCC).Methods 40 patients with chronic hepatitis B (CHB), 25 patients with compensated hepatitis B liver cirrhosis (LC), 31 patients with decompensated hepatitis B LC, 50 patients with HCC and 40 healthy persons were enrolled in our hospital between July 2017 and July 2020, and serum oncogene transformation of participants (N-ras), proliferation related genes (C-myc), fibroblast growth factor (FGF) 2, silk/threonine kinase (PLK) 1 as well as tumor-suppressor genes iron element (hepcidin), scavenger receptors (SCAR) A5, and cell cycle dependent protein kinase inhibitor (P16) protein were detected by ELISA.Results Serum N-ras, C-myc, FGF2 and PLK1 levels in patients with HCC were (17.9±2.4)pg/mL, (16.2±2.0)pg/mL,(19.0±3.2)pg/mL and (15.4±1.9)pg/mL, all significantly higher than 【(10.3±1.4)pg/mL,(10.0±1.2)pg/mL,(10.2±1.4)pg/mL and (9.0±1.1)pg/mL, respectively, P＜0.05】 in patients with decompensated LC or 【(9.9±1.2)pg/mL,(9.9±1.1)pg/mL,(10.0±1.3)pg/mL and (9.1±1.0)pg/mL, respectively,P＜0.05】 in patients with compensated LC or 【(9.8±1.1)pg/mL,(9.7±1.1)pg/mL,(9.9±1.2)pg/mL and (9.0±1.0)pg/mL, respectively, P＜0.05】 in patients with CHB or 【(1.2±0.2)pg/mL, (1.1±0.1)pg/mL, (1.1±0.2)pg/mL and (0.9±0.1)pg/mL, respectively, P＜0.05】 in healthy persons; serum hepcidin, SCARA5 and P16 levels in patients with HCC were (1.1±0.3)pg/mL,(1.3±0.3)pg/mL and (1.7±0.4)pg/mL, all significantly lower than 【(5.3±0.7)pg/mL,(7.2±1.1)pg/mL and (6.4±0.8)pg/mL, respectively, P＜0.05】 in patients with decompensated LC or 【(5.6±0.8)pg/mL,(7.3±1.1)pg/mL and (6.3±0.8)pg/mL, respectively, P＜0.05】 in patients with compensated LC or 【(5.4±0.7)pg/mL,(7.9±1.1)pg/mL and (6.5±1.0)pg/mL, respectively, P＜0.05】 in patients with CHB or 【(12.9±1.2)pg/mL, (14.4±1.3)pg/mL and (11.6±0.9)pg/mL, respectively, P＜0.05】 in healthy individuals.Conclusion The up-regulation of N-ras, c-myc, FGF2 and PLK1 and down-regulation of hepcidin, scara5 and p16 occur in patients with HCC, which might be involved in the hepatocarcinogenesis.

Key words: Hepatoma, Oncogene, Tumor suppressor gene

Chen Shaohua, Wu Zhe, Wei Zhihong, et al. Serum oncogene and tumor suppressor gene levels in patients with hepatocellular carcinoma[J]. Journal of Practical Hepatology, 2021, 24(2): 244-247.

References

[1] Jabbour TE, Lagana SM, Lee H. Update on hepatocellular carcinoma: pathologists' review. World J Gastroenterol, 2019, 25(14):1653-1665.
[2] Golabi P, Rhea L, Henry L, et al. Hepatocellular carcinoma and non-alcoholic fatty liver disease. Hepatol Int, 2019, 13(6):688-694.
[3] Budny A ,Kozłowski P , Kamińska M, et al. Epidemiology and risk factors of hepatocellular carcinoma. Pol Merkur Lekarski, 2017, 43(255):133-139.
[4] Zhou F, Shang W, Yu X, et al. Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev, 2018, 38(2):741-767.
[5] Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol, 2019, 16(10):589-604.
[6] Cartier F , Indersie E , Lesjean S, et al. New tumor suppressor microRNAs target glypican-3 in human liver cancer. Oncotarget, 2017, 8(25):41211-41226.
[7] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2019年版). 实用肝脏病杂志, 2020, 23(1):9-32.
[8] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版). 中华肝脏病杂志, 2012, 20(6):929-946.
[9] 曹艳, 王艳. 基于死因监测青岛市居民2008-2012年原发性肝癌死亡分析. 中华肿瘤防治杂志, 2017, 24(9):579-583.
[10] 管晨滔, 赵宏, 李新庆, 等. 肝细胞癌患者的基本特征及其生存分析. 中华肿瘤杂志, 2017, 39(3):231-235.
[11] 罗准, 崔巍. 肝癌分子发病机制中非编码RNA的研究进展. 中华肝脏病杂志, 2018, 26(10):797-800.
[12] Wong CM, Tsang FH, Ng IO. Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. Nat RevGastroenterol Hepatol, 2018, 15(3):137-151.
[13] Delogu S, Wang C, Cigliano A, et al. SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice. Oncotarget, 2015, 6(4):2222-2234.
[14] Kress TR, Pellanda P, Pellegrinet L, et al. Identification of MYC-dependent transcriptional programs in oncogene-addicted liver tumors. Cancer Res, 2016, 76(12):3463-3472.
[15] Chaisaingmongkol J, Budhu A, Dang H, et al. Common molecular subtypes among Asian hepatocellular carcinoma and cholangiocarcinoma. Cancer Cell, 2017, 32(1):57-70.
[16] Yim SY, Shim JJ, Shin JH, et al. Integrated genomic comparison of mouse models reveals their clinical resemblance to human liver cancer. Mol Cancer Res, 2018, 16(11):1713-1723.
[17] Katoh M. FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). Int J Mol Med, 2016, 38(1):3-15.
[18] Ruf S, Heberle AM, Langelaar-Makkinje M, et al. PLK1 (polo like kinase 1) inhibits MTOR complex 1 and promotes autophagy. Autophagy, 2017, 13(3):486-505.
[19] Zhao N, Maxson JE, Zhang RH, et al. Neogenin facilitates the induction of hepcidin expression by hemojuvelin in the liver. J Biol Chem, 2016, 291(23):12322-12335.
[20] Liu H, Hu J, Pan H, et al. CSN5 Promotes hepatocellular carcinoma progression by SCARA5 inhibition through suppressing β-catenin ubiquitination. Dig Dis Sci, 2018, 63(1):155-165.

Serum oncogene and tumor suppressor gene levels in patients with hepatocellular carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Luo Weixin, Liu Chaoqun, Xu Leibo, et al. Effects of exosomes derived from rat liver cancer cells with different lung metastasis potentials on the transcriptome of macrophages [J]. Journal of Practical Hepatology, 2021, 24(3): 312-318.
[2]	Mo Juan, Yan Wen, Xu Shaoqiang. Short-term and long-termsurvivals of patients with huge primary liver cancer after associated liver partition and portal vein ligation for staged hepatectomy [J]. Journal of Practical Hepatology, 2021, 24(2): 252-255.
[3]	Zhao Chuang, Liang Chao, Dong Baojian, et al. Analgesia of dexmedetomidine and morphine in patients with primary liver cancer undergoing transcatheter hepatic arterial chemoembolization [J]. Journal of Practical Hepatology, 2021, 24(2): 260-263.
[4]	Zhu Yaping, Wei Jinju, Wang Yanxin, et al. Continuous pumping propofol in anaesthetizing patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(2): 292-293.
[5]	Li Xiaoyan, Hu Heping. Internal management of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(1): 1-3.
[6]	Zhou Xinmin, Ding Xiaopeng. Highlights of conventional supporting therapy for patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(1): 4-6.
[7]	Liu Qi, Hao Jiqing. Immunotherapy of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(1): 7-9.
[8]	Qiao Min, Zhao Yijian,Z hang Jianqiao,et al. Efficacy of TACE and radiofrequency ablation combination in the treatment of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(1): 119-122.
[9]	Li Yamin, Wang Ruiting, Wang Yingying. Short-term efficacy of radiofrequency ablation with cold circulation in the treatment of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(1): 123-126.
[10]	Xie huanyu, Gong Jinwei, Zhao MingXing, et al. Inhibitoryeffects of Fe₃O₄ nanometer magnetic carrier-induced hyperthermia under extremely low frequency electromagnetic fields on implanted tumors in nude mice [J]. Journal of Practical Hepatology, 2020, 23(6): 777-780.
[11]	Hu Xia, Zhai Xiaofeng, Gu Wei, et al. Cyberknife stereotactic radiotherapy and transcatheter arterial chemoembolization as an option of treatment for patients with primary liver cancer [J]. Journal of Practical Hepatology, 2020, 23(6): 881-884.
[12]	Han Pengwei, Wang Huming, Zhao Tianyong. Clinical feature and prognostic factors of primary liver cancer patients with serum AFP negative after TACE [J]. Journal of Practical Hepatology, 2020, 23(5): 715-718.
[13]	Zhou Binbin,Sun Yaochen,Huang Haifan, et al.. Evaluation of functional magnetic resonance imaging in patients with hepatocellular carcinoma after TACE [J]. Journal of Practical Hepatology, 2020, 23(5): 723-726.
[14]	Liu Xu, Hu Yuchang, Cheng Lu, et al.. Clinicopathological manifestation of primary liver adenosquamous carcinoma: An analysis of six cases [J]. Journal of Practical Hepatology, 2020, 23(5): 727-730.
[15]	Liu Kewan. Liu Yuxing,Song Haiyan,et al.. Application of traditional Chinese medicineand hyperbaric oxygen after TACE for treatment of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2020, 23(5): 755-756.